|
|
|
17-20 June - BIO 2008
|
|
|
Breakout Session
Topic: Singapore - The Biopolis of Asia
Date: 19 June 2008 (Thurs)
Time: 8:30am - 10:00 am
Venue: Room 26 AB, San Diego Convention Center
Speakers:
Prof Edward Holmes,
Alexis Borisy, President and CEO, CombinatoRx,
Steven Tregay, MD, Novartis Option Fund,
William Chin, VP, Eli Lilly and Company
Participants at Singapore Pavilion
The Singapore Economic Development Board (EDB) is the lead government agency responsible for planning and executing economic strategies to enhance Singapore's position as a global hub for business and investment. We are the one-stop agency that facilitates and supports local and foreign investors in both the manufacturing and services sectors as they seek more value-creating operations, higher sustainable returns and new business opportunities.
Singapore commands global leadership positions in many areas. EDB is expanding and extending existing industry clusters, as well as exploring new growth areas to create good jobs and secure Singapore's future competitiveness. Our emphasis is on capital-intensive, knowledge-intensive and innovation-intensive activities. EDB is constantly identifying new business areas to develop both in terms of new technologies as well as new consumer demands, such as our 'clean and green' focus - environmental technologies, urban solutions and clean energy, lifestyle, healthcare and wellness. EDB is also expanding our geographical reach, such as Middle East, in addition to North America, Europe, Japan, China, India and ASEAN. For more information on how EDB can help in your business and investment, please visit www.sedb.com
Contact Person
Mr Zhi-Wei Loh
zhi_wei_loh@edb.gov.sg
Agency for Science, Technology and Research (A*STAR) is Singapore's lead agency for fostering world-class scientific research and talent for a vibrant knowledge-based Singapore.
The Biomedical Research Council (BMRC) oversees the development of core research capabilities within A*STAR research units specialising in bioprocessing; chemical synthesis; genomics and proteomics; molecular and cell biology; bioengineering and nanotechnology and computational biology. Through competitive grants, the Council also supports research in the wider scientific community such as public universities and hospitals. As part of its efforts to advance human healthcare, BMRC actively promotes translational medicine and cross-disciplinary research. The Council also engages in human capital development in the biomedical sciences and promotes societal awareness of biomedical research through outreach programmes. For more information, please visit our website: http://www.a-star.edu.sg
Bio*One Capital is a leading, dedicated biomedical sciences investment management company in Asia with a worldwide presence. Bio*One Capital's investments are focused on promising global biomedical companies where Bio*One Capital can play a value adding role in bridging and supporting companies' growth strategies in Asia through their operations in Singapore. A part of the Singapore Economic Development Board, Bio*One Capital oversees a portfolio of over 50 companies in the US, Europe, Singapore and Asia. For more information, please visit http://www.bio1capital.com
A-Bio Pharma Pte Ltd, Asia's leading biologics contract manufacturer, provides a full range of manufacturing solutions for mammalian cell culture systems, including process development, optimisation, manufacturing scale-up, GMP production, quality control and regulatory compliance. Based in Singapore, we leverage on the excellent business and manufacturing infrastructure, as well as the rapidly growing Biomedical Sciences cluster in the island state. Our aim is to be the preferred manufacturing partner for pharmaceutical and biotechnology companies seeking to bring their products to the market in a timely and cost-effective manner. For more information, please visit www.a-bio.com
Contact Person
Dr Kean-Chong Loh
KeanChong.Loh@a-bio.com
Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models. For more information, please visit www.AMRIglobal.com
Contact Person
Mr Raymond Yeung
Raymond.Yeung@amriglobal.com
Ascendas is Asia's leading provider of business space solutions with key markets in Singapore, China, India and South Korea. Based in Singapore, Ascendas has built a strong regional presence from over 20 years of serving a global clientele of more than 1,300 customers. It specializes in developing, managing and marketing science/IT parks, industrial parks, business parks, hi-tech facilities and office space. In Singapore, Ascendas plays an important role in shaping the business landscape of knowledge-based, hi-tech activities. Its portfolio includes the Singapore Science Park, a reputed global hub for R&D, and two life sciences buildings, named Neuros and Immunos, in Biopolis. For more information, please visit www.ascendas.com
Contact Person
Ms Eunice Ow
eunice.ow@ascendas.com
CellResearch Corporation is a Singapore-based company with IPR to an ethical high yielding source of infant stem cells, derived from the outer lining of the umbilical cord. Successfully differentiated into a variety of cell types, these Cord Lining Stem Cells are opening new frontiers in stem cell development. Current collaborations span wound and diabetes management, bone/cartilage and cardiac repair, nerve regeneration, cosmeceuticals and cord stem cell banking services. New collaborations and ventures with parties keen on cell therapy and/or stem cell research are welcomed. We are also a leading supplier of high quality skin cells (normal/diseased) for in-vitro experimentation and are a customised contract research service provider. For more information, please visit www.cellresearchcorp.com
Contact Person
Mr Edwin Chow
edwinchow@cellresearchcorp.com
Entrepreneur-driven, headquartered in Singapore and with an expanding regional footprint, Crescendas Group is engaged in a diversified range of businesses in Real Estate, Manufacturing, Distribution and Technology. The Group's facilities and operations are in Singapore, Malaysia, Vietnam, Laos, the People's Republic of China and Germany. For more information, please visit www.crescendas.com
Contact Person
Mr Soon-Lee Onn
slonn@crescendas.com
The Experimental Therapeutics Centre (ETC) is organized around core technologies and innovative scientific programs to perform translational work. It has a corporate structure with experienced management and scientific oversight to facilitate the discovery, development and pre-clinical evaluation of potential diagnostics and therapeutics. The management team, led by CEO Professor Sir David Lane, is drawn from industry and academia. ETC incubates new technologies for commercialization and mentors young scientists for careers in the pharmaceutical and biotech industry. For more information, please visit www.etc.a-star.edu.sg
Contact Person
Mr Thomas Condon
tcondon@etc.a-star.edu.sg
i-DNA Biotechnology Pte Ltd is a biotech product- and service-oriented company. The focus of i-DNA is to develop, manufacture, market and distribute innovative products and services for applications in the areas of life sciences, biotechnology and laboratory molecular diagnosis. i-DNA serves as:distributor for many finest and specialized international brands; provider for custom services such as DNA paternity testing, genotyping; gene expression profiling; cytokine profiling and antibody production for research uses; manufacturer of common research reagents and buffers; partner for new product and service development; business incubator for innovations and company spin-off. i-DNA strives to be a decisive biotech company to meet the varying needs of our customers and the industry. We welcome your enquiry. www.i-dna.biz / www.i-dna.sg
Contact Person
Ms Amethyst Woe
amethyst@i-dna.biz
JTC Corporation is the lead agency in Singapore to plan, promote and develop a dynamic industrial landscape. It is the master developer for one-north, a 200-hectare development for research and entrepreneurial activities. Biopolis, located within one-north, is a vibrant hotspot for biomedical R&D activities and an ideal environment to spur new discoveries and advances in the biomedical sciences. For more information, please visit www.jtc.gov.sg.
Contact Person
Ms Vivien Tay
marketing@one-north.com
Maccine. Toxicological and cardiovascular safety assessment for human therapeutics is offered through state-of-the-art AAALAC accredited and GLP compliant laboratories. Operating at the forefront of non human primate research, the laboratory focus is on enhanced prognostic value and translation to the clinic. A portfolio of efficacy models in key therapeutic areas is backed by high level analytical and imaging support with the objective to remain the preclinical partner of choice in Asia. For more information, please visit www.maccine.com
Contact Person
Ms Jody Sawyer
business.development@maccine.com
S*BIO Pte Ltd focuses on creating a "best-in-class" portfolio of novel small molecule therapeutics for cancer. S*BIO utilizes its fully integrated drug discovery engine, clinical network and development capabilities to rapidly advance its proprietary anti-cancer agents to the clinic. S*BIO's lead candidate, SB939, entered the clinic in 2Q 2007. It recently announced that a second compound, SB1518, would enter the clinic in 1H 2008 and that a third compound, SB1317 is in preclinical development. For more information, please visit www.sbio.com
Contact Person
Dr Stephen Rhind
stephen_rhind@sbio.com
|
|
|
|
|
|
|
|
